

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

FOR THE MONTH OF NOVEMBER 2021

COMMISSION FILE NUMBER 001-39081

BioNTech SE

(Translation of registrant's name into English)

**An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F
Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On November 26, 2021, the Financial Times published an article that BioNTech SE (the “Company”) will take two weeks to assess the Pfizer-BioNTech COVID-19 Vaccine against the new B.1.1.529 variant of COVID-19 that has emerged in southern Africa. The press releaseARTICLE is attached hereto as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By: /s/ Dr. Sierk Poetting

Name: Dr. Sierk Poetting

Title: Chief Operating Officer

Date: November 26, 2021

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	BioNTech will take two weeks to assess vaccine against latest Covid variant.

NOV 26, 2021 - 13:24

BioNTech will take two weeks to assess vaccine against latest Covid variant

Hannah Kuchler

BioNTech will know in two weeks whether the vaccine it developed with Pfizer will work against the new B.1.1.529 variant of Covid that has emerged in southern Africa.

The German company says it is testing the vaccine against the strain in the lab. It said the variant “differs significantly from previously observed variants” because of additional mutations on the spike protein, which vaccines target.

“Pfizer and BioNTech have taken actions months ago to be able to adapt the mRNA vaccine within six weeks and ship initial batches within 100 days in the event of an escape variant,” the company said.

“To that end, the companies have begun clinical trials with variant-specific vaccines (alpha and delta) to collect safety and tolerability data that can be provided to regulators.”

Shares in BioNTech climbed 7.2 per cent to \$326.56 in pre-market trading, while partner Pfizer added 5.6 per cent to \$53.75.